Similar Search Results

The role of government reimbursement in drug shortages

Yurukoglu, Ali; Liebman, Eli; Ridley, David B. - In: American economic journal : a journal of the American … 9 (2017) 2, pp. 348-382

Persistent link: https://www.econbiz.de/10011660322

Has pharmaceutical innovation reduced the average cost of U.S. health care episodes?

Lichtenberg, Frank R. - In: International journal of health economics and management 24 (2024) 1, pp. 1-31

Persistent link: https://www.econbiz.de/10014547929

Private Vaccination and Public Health : An Empirical Examination for U.S. Measles

Philipson, Tomas - 2008

This paper investigates the degree to which the occurrence of vaccine-preventable diseases affects vaccination efforts against such diseases. Using data from the National Health Interview Survey on measles vaccinations in the United States between 1984 and 1990, the paper shows there is strong...

Persistent link: https://www.econbiz.de/10014108473

Rationing Medicine Through Bureaucracy : Authorization Restrictions in Medicare

Brot-Goldberg, Zarek C.; Burn, Samantha; Layton, Timothy; … - National Bureau of Economic Research - 2023

High administrative costs in U.S. health care have provoked concern among policymakers over potential waste, but many of these costs are generated by managed care policies that trade off bureaucratic costs against reductions in moral hazard. We study this trade-off for prior authorization...

Persistent link: https://www.econbiz.de/10013537772

Regulatory Incentives for Innovation : The FDA's Breakthrough Therapy Designation

Chandra, Amitabh; Kao, Jennifer L.; Miller, Kathleen L.; … - National Bureau of Economic Research - 2022

Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to innovate around this...

Persistent link: https://www.econbiz.de/10013477204

An Ounce of Prevention or a Pound of Cure? Short- and Long-Run Effects of Pharmaceutical Patents on U.S. Health Care Expenditures

Johnson, Hilary S.; Johnson, Daniel K. N. - 2014

driving the costs of pharmaceuticals, and develop a structured vector autoregressive (SVAR) model to measure the social rate …-run prices in pharmaceuticals themselves, but with lower long-run prices in the aggregate medical sector which includes … pharmaceuticals as a component part. Further, the TRIPS Agreement and Hatch-Waxman Act to enable generic competition have both been …

Persistent link: https://www.econbiz.de/10014209235

Integrierte Versorgung und die Rolle der Pharmaindustrie

Koch, Kristian - 2009

Persistent link: https://www.econbiz.de/10003862841

Die Kosten-Nutzen-Analyse : Methodik und Anwendung am Beispiel von Medikamenten

Horisberger, Bruno (ed.) - 1986

Persistent link: https://www.econbiz.de/10008731617

Gute Qalys, schlechte Qalys?

Staat, Matthias - In: Gesundheits- und Sozialpolitik : Zeitschrift für das … 61 (2007) 7/8, pp. 8-13

Persistent link: https://www.econbiz.de/10003534379

The effects of rebate contracts on the health care system

Graf, Julia - 2012

Group Purchasing Organizations (GPOs) increasingly gain in importance with respect to the supply of pharmaceutical products and frequently use multiple or exclusive rebate contracts to exercise market power. Based on a Hotelling model of horizontal and vertical product differentiation, we...

Persistent link: https://www.econbiz.de/10009510114